74: Sirolimus (SRL)-based GVHD prophylaxis to decrease relapse in pediatric related and unrelated transplant recipients with very high-risk all Preliminary results of a multi-institutional pilot study by Pulsipher, M.A. et al.
1 secondary RA; 1 RAEB in CR1), and JMML (1 PR3). Patients
received busulfan 0.8mg/kg/dose IV x 8 doses (target AUC
900-1100 uM/min), ﬂudarabine 30mg/m2/d x 6 days, and thy-
moglobulin, 2.5 mg/m2/d x 1 day for RD and x 4 days for UD
and UCB. Two pts rejected their grafts, one after a mismatched
RD-BM, and a second after UD-BM. Two pts died prior to day
100 due to toxicity (6%) and the overall NRM is 16%. Acute
GVHD (grade I-II) occurred in 3/25 (12%, no grade III-IV) and
chronic GVHD occurred in 4/18 (22%) evaluable pts. Median
follow up is 12 months (range 1-35 m). Of 30 pts 30 days out
from transplant, 10 pts relapsed. Two year EFS and OS are 49%
(SE 9.8) and 49% (SE 11%), respectively. Two relapsed pts are
alive at 5 and 1 months after a second transplant and DLI,
respectively. One patient who rejected received a second RIC,
engrafted, and is alive with cGVHD. Of the 8 pts surviving
more than one year from transplant, 4 had AML/MDS (2 in
CR2; 1 secondary AML; 1 secondary MDS), 3 had ALL (1 in
CR2; 2 in CR3,), and 1 had HD in CR3. In conclusion, RIC
using bu/ﬂu/ATG in a large cooperative group setting leads to
engraftment in 90% of very high risk pediatric pts using a
variety of stem cell sources. In spite of signiﬁcant prior therapy
and comorbidities in this cohort, rates of NRM and GVHD are
low. Prolonged relapse free survival has occurred not only in pts
with myeloid disease as expected, but also in pts with ALL and
lymphoma. Flu/bu/ATG is a promising therapeutic approach
for pediatric pts otherwise ineligible for myeloablative trans-
plant.
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Relapse and NRM after allogeneic SCT remain signiﬁcant bar-
riers to success in treating very high-risk ALL. Preclinical models
have shown activity of SRL against human ALL, causing apoptosis
and cell death at serum levels used for immune suppression. We
hypothesized that SRL would decrease relapse after HSCT for
ALL, with acceptable rates of GVHD, thus improving EFS. This
multi-center pilot trial assessed the feasibility/toxicity of SRL-
based GVHD prophylaxis in RD, UD, and UCB HSCT. After a
preparative regimen of TBI, thiotepa and cyclophosphamide, pts
received continuous IV tacrolimus (start d-2, target 5-10ng/mL),
PO sirolimus (start d0, target 3-12ng/mL), and IV methotrexate
(MTX; 5mg/m2, d1,3, and6 plus d11 for recipients of UD
BM/PBSC). Tacrolimus was tapered between d42-96 for MSD
and d100-180 for others. Sirolimus was tapered over 4 wks
starting at 6m after transplant. Thirty two patients have been
enrolled, with a median age of 9 yrs (1-18). Immunophenotypes
included pre-B 24, T-cell 7, and MLL 1. Six patients were in VHR
CR1, 17 were in CR2 (9 CR1 18 months), and 8 were in CR3.
Stem cell sources included UCB 16, MSD-BM 14, 5/6 mismatched
RD-BM 1, 9/10 mismatched UD-PBSC 1. SRL was successfully
administered to all pts and therapeutic drug levels achieved. Four
patients had SRL held brieﬂy for high levels or toxicity and three
patients stopped due to toxicity (VOD/TAM). Engraftment oc-
curred in 29 of 31 evaluable pts at median of 20d (13-62); one CB
recipient engrafted successfully after a second infusion and a sec-
ond patient relapsed prior to engraftment. Overall grade II-III
aGVHD occurred in 11/31 evaluable pts (35%, no grade IV). 4/19
(21%) of evaluable patients developed cGVHD. Relapses occurred
in 5 pts at a median of 94 days (34-362). NRM occurred in 3
patients (9%). Other signiﬁcant toxicities included one pt with IPS
requiring intubation (resolved), one nonfatal VOD, one pericardial
effusion, and two cases of reversible TAM. With a median f/u of
9m (1-38m) the 1 yr EFS and OS are 71.4% (SE 10.6) and 80.3%
(SE 7.2), respectively. In this very high risk cohort of children with
ALL, we have demonstrated that GVHD prophylaxis with SRL,
tacrolimus, and MTX is feasible using multiple stem cell sources,
resulting in low rates of NRM, acute and chronic GVHD, and
relapse. A randomized phase III trial comparing this regimen to
tacrolimus/MTX in children undergoing HSCT for ALL is open-
ing soon through the Children’s Oncology Group.
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Children with severe organ toxicities, DNA repair disorders
and infants 1 year tolerate existing conditioning regimens,
including reduced intensity conditioning, poorly. To reduce
TRM in such patients, we used a minimal intensity conditioning
regimen utilising 2 rat anti-CD45 monoclonal antibodies
(Mabs) YTH24.5/YTH 54.12 for myelosuppression and Ale-
mtuzumab (anti-CD52) for immunosuppression. As CD45 is
expressed selectively on haemopoietic cells, the Mabs provide
immunosuppression and transient myeloablation without the
systemic toxicity associated with chemotherapy. 14 children (5
SCID, 5 CID, 2 dyskeratosis congenita, 1 reticular dysgenesis, 1
HLH) were transplanted at a median age of 13 months (5
months-11 years). Inclusion criteria were primary immunodeﬁ-
ciency (PID) in children age 1 (n7), severe organ toxicity
(n12) and DNA repair defects/radiation sensitivity (n4). Do-
nors were MSD (n4), MUD (n9) and MMUD (n2). Organ
toxicity was deﬁned as a) O2 requirement at BMT/prior venti-
lation, b) FEV1 or FVC  60% predicted, c) Bilirubin 50 mM
or ALT 4 x normal or d) TPN dependent enteropathy. The
conditioning regimen consisted of Alemtuzumab 0.2mg/kg x 3
(MUD) or 0.1mg/kg x 3 (MSD) on D-8 to –6, YTH 24.5/54.12
0.4mg/kg on D-5 to D-2, with Fludarabine 150mg/m2 and
Cyclophosphamide 1200mg/m2. GVHD prophylaxis was with
CSA and MMF. Stem cell source was PBSC in 5/14 patients,
BM in 8/14 and cord blood in 1/14.
The Mabs were well tolerated. Median time to neutrophil recov-
ery  0.5  109/L was 9 days (range 0-15). The patient who
received a MMUD cord blood graft rejected. 12/13 evaluable
patients who received BM/PBSC engrafted. 7/13 patients achieved
100% donor chimerism, 4/13 high level mixed chimerism (MC) in
both myeloid and lymphoid lineages and 1/13 low level MC. Six
patients developed signiﬁcant aGVHD (3 grade 2, 3 grade 3). Since
BM has been used as the stem cell source, only 1/8 has had
GVHD  grade 3. 4/10 evaluable patients have cGVHD (limited
n2;extensive n2). At a median follow up of 13 months, all
patients are alive. 12/13 are stably engrafted and those with  6
months follow-up have good immune reconstitution. In summary,
Mab-based conditioning is well tolerated and achieves engraftment
even in patients with severe organ toxicity or DNA repair defects,
with a short period of neutropenia. The protocol enables trans-
plantation in patients who previously would not be candidates for
such a procedure and may additionally reduce late effects.
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